All In Biotech

Drug Trial Radar · NCT06710925

A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Monoclonal Antibody TNM001 Injection Against Respiratory Syncytial Virus in High-risk Infants

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

315

Actual

Start

Nov 28, 2024

Primary completion

Jul 27, 2025

Study completion Dec 14, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 0 weeks, up to 12 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and immunogenicity of TNM001 in high-risk infants when entering their RSV season. Approximately 201 infants will be randomized in a ratio of 2:1 to receive TNM001 or placebo. All subjects will be followed for 270 days after dosing. This study will be conducted at approximately 20 sites in China.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • TNM001Biological

    single dose intramuscular injection

  • placeboBiological

    single dose intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of medically attended LRTI due to RT-PCR confirmed RSVTime frame: 150 days post dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • West China Second University Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Children's Hospital of Chongqing Medical University

    Chongqing, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.